NASDAQ:ADAG Adagene (ADAG) Stock Price, News & Analysis $1.56 -0.11 (-6.61%) Closing price 03/28/2025 03:57 PM EasternExtended Trading$1.56 +0.01 (+0.58%) As of 03/28/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Adagene Stock (NASDAQ:ADAG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Adagene alerts:Sign Up Key Stats Today's Range$1.51▼$1.6150-Day Range$1.56▼$2.1052-Week Range$1.39▼$3.58Volume22,886 shsAverage Volume60,308 shsMarket Capitalization$73.26 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingModerate Buy Company OverviewAdagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Read More… Remove Ads Adagene Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreADAG MarketRank™: Adagene scored higher than 46% of companies evaluated by MarketBeat, and ranked 630th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAdagene has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAdagene has only been the subject of 2 research reports in the past 90 days.Read more about Adagene's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Adagene are expected to decrease in the coming year, from ($0.60) to ($0.76) per share.Price to Book Value per Share RatioAdagene has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.05% of the float of Adagene has been sold short.Short Interest Ratio / Days to CoverAdagene has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adagene has recently increased by 3.39%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdagene does not currently pay a dividend.Dividend GrowthAdagene does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.05% of the float of Adagene has been sold short.Short Interest Ratio / Days to CoverAdagene has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adagene has recently increased by 3.39%, indicating that investor sentiment is decreasing. News and Social Media2.3 / 5News Sentiment0.21 News SentimentAdagene has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Adagene this week, compared to 1 article on an average week.Search Interest4 people have searched for ADAG on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adagene insiders have not sold or bought any company stock.Percentage Held by Insiders21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.51% of the stock of Adagene is held by institutions.Read more about Adagene's insider trading history. Receive ADAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAG Stock News HeadlinesAdagene Reports 33% Overall Response Rate in Phase 2 Expansion of Muzastotug for MSS CRC, Highlights Financial Position and Future MilestonesMarch 26, 2025 | nasdaq.comAdagene (ADAG) Projected to Post Earnings on ThursdayMarch 25, 2025 | americanbankingnews.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.March 30, 2025 | Porter & Company (Ad)Adagene reports FY24 adjusted EPS (51c), consensus (58c)March 25, 2025 | markets.businessinsider.comAdagene Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 25, 2025 | markets.businessinsider.comAdagene Inc. Reports 2024 Financial Results and ProgressMarch 25, 2025 | tipranks.comAdagene Reports 2024 Financial Results and Advances Clinical ProgramsMarch 24, 2025 | tipranks.comAdagene Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 24, 2025 | globenewswire.comSee More Headlines ADAG Stock Analysis - Frequently Asked Questions How have ADAG shares performed this year? Adagene's stock was trading at $1.99 at the start of the year. Since then, ADAG shares have decreased by 21.9% and is now trading at $1.5550. View the best growth stocks for 2025 here. When did Adagene IPO? Adagene (ADAG) raised $133 million in an initial public offering (IPO) on Tuesday, February 9th 2021. The company issued 7,400,000 shares at $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies served as the underwriters for the IPO and China Renaissance was co-manager. Who are Adagene's major shareholders? Top institutional investors of Adagene include General Atlantic L.P. (8.64%), FIL Ltd (7.40%), Mill Creek Capital Advisors LLC (0.45%) and Kamunting Street Capital Management L.P. (0.28%). How do I buy shares of Adagene? Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adagene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adagene investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD) and Adobe (ADBE). Company Calendar Today3/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADAG CIK1818838 Webwww.adagene.com Phone86-512-8777-3632FaxN/AEmployees260Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+414.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.08 Current Ratio2.50 Quick RatioN/A Sales & Book Value Annual Sales$103,204.00 Price / Sales709.82 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book0.97Miscellaneous Outstanding Shares47,110,000Free Float34,886,000Market Cap$73.26 million OptionableNot Optionable Beta0.50 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:ADAG) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | SponsoredTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.